Oxidants and antioxidants in atherogenesis: An appraisal

Journal of Lipid Research

Volumn 40, Issue 12, 1999, Pages 2143-2157

  Parthasarathy, Sampath ^a   Santanam, Nalini ^a   Ramachandran, Sumathi ^a   Meilhac, Olivier ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antioxidants; Atherosclerosis; LDL; Lipid peroxides; Prooxidants

Indexed keywords

ANTIOXIDANT; LOW DENSITY LIPOPROTEIN; OXIDIZING AGENT;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; COMPETITIVE INHIBITION; ESTERIFICATION; FOAM CELL; LIPID BLOOD LEVEL; LIPID OXIDATION; LIPID PEROXIDATION; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTIOXIDANTS; ARTERIOSCLEROSIS; HUMANS; LIPOPROTEINS, LDL; OXIDANTS;

EID: 0033372489     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (154)

1. Steinberg, D., S. Parthasarathy, T. E. Carew, J. C. Khoo, and J. L. Witztum. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity [see comments]. N. Engl. J. Med. 320: 915-924.
2. Parthasarathy, S., N. Santanam, and N. Auge. 1998. Oxidized low-density lipoprotein, a two-faced Janus in coronary artery disease? Biochem. Pharmacol. 56: 279-284.
3. Tribble, D. L. 1999. AHA Science Advisory. Antioxidant consumption and risk of coronary heart disease: emphasis on vitamin C, vitamin E, and beta-carotene: a statement for healthcare professionals from the American Heart Association. Circulation. 99: 591-595.
4. Parthasarathy, S., E. Wieland, and D. Steinberg. 1989. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc. Natl. Acad. Sci. USA. 86: 1046-1050.
5. Yla-Herttuala, S., M. E. Rosenfeld, S. Parthasarathy, C. K. Glass, E. Sigal, J. L. Witztum, and D. Steinberg. 1990. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc. Natl. Acad. Sci. USA. 87: 6959-6963.
6. Yla-Herttuala, S., M. E. Rosenfeld, S. Parthasarathy, E. Sigal, T. Sarkioja, J. L. Witztum, and D. Steinberg. 1991. Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J. Clin. Invest. 87: 1146-1152.
7. Cyrus, T., J. L. Witztum, D. J. Rader, R. Tangirala, S. Fazio, M. F. Linton, and C. D. Funk. 1999. Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice [In Process Citation]. J. Clin. Invest. 103: 1597-1604.
8. Brown, M. S., S. K. Basu, J. R. Falck, Y. K. Ho, and J. L. Goldstein. 1980. The scavenger cell pathway for lipoprotein degradation: specificity of the binding site that mediates the uptake of negatively-charged LDL by macrophages. J. Supramol. Struct. 13: 67-81.
9. Henriksen, T., E. M. Mahoney, and D. Steinberg. 1981. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc. Natl. Acad. Sci. USA. 78: 6499-6503.
10. Steinbrecher, U. P., M. Lougheed, W. C. Kwan, and M. Dirks. 1989. Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. J. Biol. Chem. 264: 15216-15223.
11. Haberland, M. E., G. M. Fless, A. M. Scanu, and A. M. Fogelman. 1992. Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J. Biol. Chem. 267: 4143-4151.
12. Endemann, G., L. W. Stanton, K. S. Madden, C. M. Bryant, R. T. White, and A. A. Protter. 1993. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268: 11811-11816.
13. Ling, W., M. Lougheed, H. Suzuki, A. Buchan, T. Kodama, and U. P. Steinbrecher. 1997. Oxidized or acetylated low density lipoproteins are rapidly cleared by the liver in mice with disruption of the scavenger receptor class A type I/II gene. J. Clin. Invest. 100: 244-252.
14. Calvo, D., D. Gomez-Coronado, M. A. Lasuncion, and M. A. Vega. 1997. CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins. Arterioscler. Thromb. Vasc. Biol. 17: 2341-2349.
15. Hoshikawa, H., T. Sawamura, M. Kakutani, T. Aoyama, T. Nakamura, and T. Masaki. 1998. High affinity binding of oxidized LDL to mouse lectin-like oxidized LDL receptor (LOX-1). Biochem. Biophys. Res. Commun. 245: 841-846.
16. Steinbrecher, U. P. 1999. Receptors for oxidized low density lipoprotein. Biochim. Biophys. Acta. 1436: 279-298.
17. Bird, D. A., K. L. Gillotte, S. Horkko, P. Friedman, E. A. Dennis, J. L. Witztum, and D. Steinberg. 1999. Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: implications with respect to macrophage recognition of apoptotic cells. Proc. Natl. Acad. Sci. USA. 96: 6347-6352.
18. Santanam, N., and S. Parthasarathy. 1995. Paradoxical actions of antioxidants in the oxidation of low density lipoprotein by peroxidases. J. Clin. Invest. 95: 2594-2600.
19. Staprans, I., J. H. Rapp, X. M. Pan, and K. R. Feingold. 1996. Oxidized lipids in the diet are incorporated by the liver into very low density lipoprotein in rats. J. Lipid Res. 37: 420-430.
20. Stafforini, D. M., T. M. McIntyre, M. E. Carter, and S. M. Prescott. 1987. Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J. Biol. Chem. 262: 4215-4222.
21. Napoli, C., G. Ambrosio, G. Palumbo, P. P. Elia, and M. Chiariello. 1991. Human low-density lipoproteins are peroxidized by free radicals via chain reactions triggered by the superoxide radical. Cardiologia. 36: 527-532.
22. Hogg, N., V. M. Darley-Usmar, A. Graham, and S. Moncada. 1993. Peroxynitrite and atherosclerosis. Biochem. Soc. Trans. 21: 358-362.
23. Patel, R. P., and V. M. Darley-Usmar. 1996. Using peroxynitrite as oxidant with low-density lipoprotein. Methods Enzymol. 269: 375-384.
24. Heinecke, J. W. 1997. Pathways for oxidation of low density lipoprotein by myeloperoxidase: tyrosyl radical, reactive aldehydes, hypochlorous acid and molecular chlorine. Biofactors. 6: 145-155.
25. Rankin, S. M., S. Parthasarathy, and D. Steinberg. 1991. Evidence for a dominant role of lipoxygenase(s) in the oxidation of LDL by mouse peritoneal macrophages. J. Lipid Res. 32: 449-456.
26. Watson, A. D., N. Leitinger, M. Navab, K. F. Faull, S. Horkko, J. L. Witztum, W. Palinski, D. Schwenke, R. G. Salomon, W. Sha, G. Subbanagounder, A. M. Fogelman, and J. A. Berliner. 1997. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J. Biol. Chem. 272: 13597-13607.
27. Leitinger, N., A. D. Watson, S. Y. Hama, B. Ivandic, J. H. Qiao, J. Huber, K. F. Faull, D. S. Grass, M. Navab, A. M. Fogelman, F. C. de Beer, A. J. Lusis, and J. A. Berliner. 1999. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler. Thromb. Vasc. Biol. 19: 1291-1298.
28. Ivandic, B., L. W. Castellani, X. P. Wang, J. H. Qiao, M. Mehrabian, M. Navab, A. M. Fogelman, D. S. Grass, M. E. Swanson, M. C. de Beer, F. de Beer, and A. J. Lusis. 1999. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 19: 1284-1290.
29. Berliner, J., N. Leitinger, A. Watson, J. Huber, A. Fogelman, and M. Navab. 1997. Oxidized lipids in atherogenesis: formation, destruction and action. Thromb. Haemost. 78: 195-199.
30. Goldstein, J. L., M. S. Brown, R. G. Anderson, D. W. Russell, and W. J. Schneider. 1985. Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Annu. Rev. Cell Biol. 1: 1-39.
31. Berliner, J. A., M. Territo, M. Navab, A. Andalibi, F. Parhami, F. Liao, J. Kim, S. Estworthy, A. J. Lusis, and A. M. Fogelman. 1992. Minimally modified lipoproteins in diabetes. Diabetes. 41 Suppl 2: 74-76.
32. Sigari, F., C. Lee, J. L. Witztum, and P. D. Reaven. 1997. Fibroblasts that overexpress 15-lipoxygenase generate bioactive and minimally modified LDL. Arterioscler. thromb. Vasc. Biol. 17: 3639-3645.
33. Ezaki, M., J. L. Witztum, and D. Steinberg. 1995. Lipoperoxides in LDL incubated with fibroblasts that overexpress 15-lipoxygenase. J. Lipid Res. 36: 1996-2004.
34. Steinbrecher, U. P., J. L. Witztum, S. Parthasarathy, and D. Steinberg. 1987. Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL. Correlation with changes in receptor-mediated catabolism. Arteriosclerosis. 7: 135-143.
35. Esterbauer, H., J. Gebicki, H. Puhl, and G. Jurgens. 1992. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radical Biol. Med. 13: 341-390.
36. Parthasarathy, S. 1994. Modified Lipoproteins in the Pathogenesis of Atherosclerosis. R. G. Landes Co, Austin, TX. 152 pp.
37. Yoshida, H., O. Quehenberger, N. Kondratenko, S. Green, and D. Steinberg. 1998. Minimally oxidized low-density lipoprotein increases expression of scavenger receptor A, CD36, and macrosialin in resident mouse peritoneal macrophages. Arterioscler. Thromb. Vasc. Biol. 18: 794-802.
38. Han, J., D. P. Hajjar, J. M. Tauras, and A. C. Nicholson. 1999. Cellular cholesterol regulates expression of the macrophage type B scavenger receptor, CD36. J. Lipid Res. 40: 830-838.
39. Thomas, J. P., P. G. Geiger, M. Maiorino, F. Ursini, and A. W. Girotti. 1990. Enzymatic reduction of phospholipid and cholesterol hydroperoxides in artificial bilayers and lipoproteins. Biochim. Biophys. Acta. 1045: 252-260.
40. Christison, J., A. Karjalainen, J. Brauman, F. Bygrave, and R. Stocker. 1996. Rapid reduction and removal of HDL- but not LDL-associated cholesteryl ester hydroperoxides by rat liver perfused in situ. Biochem. J. 314: 739-742.
41. Steinbrecher, U. P., S. Parthasarathy, D. S. Leake, J. L. Witztum, and D. Steinberg. 1984. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA. 81: 3883-3887.
42. Itabe, H., E. Takeshima, H. Iwasaki, J. Kimura, Y. Yoshida, T. Imanaka, and T. Takano. 1994. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J. Biol. Chem. 269: 15274-15279.
43. Horkko, S., E. Miller, F. Dudl, P. Reaven L. K. Curtiss, N. J. Zvaifler, R. Terkeltaub, S. S. Pierangeli, D. W. Branch, W. Palinski, and J. L. Witztum. 1996. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J. Clin. Invest. 98: 815-825.
44. Horkko, S., D. A. Bird, E. Miller, H. Itabe, N. Leitinger, G. Subbanagounder, J. A. Berliner, P. Friedman, E. A. Dennis, L. K. Curtiss, W. Palinski, and J. L. Witztum. 1999. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103: 117-128.
45. Ku, G., C. E. Thomas, A. L. Akeson, and R. L. Jackson. 1992. Induction of interleukin 1 beta expression from human peripheral blood monocyte-derived macrophages by 9-hydroxyoctadecadienoic acid. J. Biol. Chem. 267: 14183-14188.
46. Thomas, C. E., R. L. Jackson, D. F. Ohlweiler, and G. Ku. 1994. Multiple lipid oxidation products in low density lipoproteins induce interleukin-1 beta release from human blood mononuclear cells. J. Lipid Res. 35: 417-427.
47. Berliner, J. A., M. C. Territo, A. Sevanian, S. Ramin, J. A. Kim, B. Bamshad, M. Esterson, and A. M. Fogelman. 1990. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J. Clin. Invest. 85: 1260-1266.
48. Fong, L. G., S. Parthasarathy, J. L. Witztum, and D. Steinberg. 1987. Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J. Lipid Res. 28: 1466-1477.
49. Kamido, H., A. Kuksis, L. Marai, and J. J. Myher. 1992. Identification of cholesterol-bound aldehydes in copper-oxidized low density lipoprotein. FEBS. Lett. 304: 269-272.
50. Hoppe, G., A. Ravandi, D. Herrera, A. Kuksis, and H. F. Hoff. 1997. Oxidation products of cholesteryl linoleate are resistant to hydrolysis in macrophages, form complexes with proteins, and are present in human atherosclerotic lesions. J. Lipid Res. 38: 1347-1360.
51. Young, S. G., and S. Parthasarathy. 1994. Why are low-density lipoproteins atherogenic? [see comments]. West. J. Med. 160: 153-164.
52. Khan, B. V., S. S. Parthasarathy, R. W. Alexander, and R. M. Medford. 1995. Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J. Clin. Invest. 95: 1262-1270.
53. Quinn, M. T., S. Parthasarathy, and D. Steinberg. 1988. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc. Natl. Acad. Sci. USA. 85: 2805-2809.
54. McMurray, H. F., S. Parthasarathy, and D. Steinberg, 1993. Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J. Clin. Invest. 92: 1014-1008.
55. Ramboer, I., P. Blin, G. Lacape, D. Daret, J. M. Lamaziere, and J. Larrue. 1992. Effects of monohydroxylated fatty acids on arterial smooth muscle cell properties. Kidney Int. Suppl. 37: S67-S72.
56. Chatterjee, S., and N. Ghosh. 1996. Oxidized low density lipoprotein stimulates aortic smooth muscle cell proliferation. Glycobiology. 6: 303-311.
57. Auge, N., I. Esrargueil-Blanc, I. Lajoie-Mazenc, I. Suc, N. Andrieu-Abadie, M. T. Pieraggi, M. Chatelut, J. C. Thiers, J. P. Jaffrezou, G. Laurent, T. Levade, A. Negre-Salvayre, and R. Salvayre. 1998. Potential role for ceramide in mitogen-activated protein kinase activation and proliferation of vascular smooth muscle cells induced by oxidized low density lipoprotein. J. Biol. Chem. 273: 12893-12900.
58. Malden, L. T., A. Chait, E. W. Raines, and R. Ross. 1991. The influence of oxidatively modified low density lipoproteins on expression of platelet-derived growth factor by human monocyte-derived macrophages. J. Biol. Chem. 266: 13901-13907.
59. Kume, N., M. I. Gybulsky, and M. A. Gimbrone, Jr. 1992. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J. Clin. Invest. 90: 1138-1144.
60. Murohara, T., R. Scalia, and A. M. Lefer, 1996. Lysophosphatidylcholine promotes P-selectin expression in platelets and endothelial cells. Possible involvement of protein kinase C activation and its inhibition by nitric oxide donors. Circ. Res. 78: 780-789.
61. Erl, W., P. C. Weber, and C. Weber. 1998. Monocytic cell adhesion to endothelial cells stimulated by oxidized low density lipoprotein is mediated by distinct endothelial ligands. Atherosclerosis. 136: 297-303.
62. Lafont, A. M., Y. C. Chai, J. F. Cornhill, P. I., Whitlow, P. H. Howe, and G. M. Chisolm. 1995. Effect of alpha-tocopherol on restenosis after angioplasty in a model of experimental atherosclerosis. J. Clin. Invest. 95: 1018-1025.
63. Lahteenmaki, T. A., R. Korpela, M. J. Tikkanen, K. Karjala, J. Laakso, E. Solatunturi, and H. Vapaatalo. 1998. Proliferative effects of oxidized low-density lipoprotein on vascular smooth muscle cells: role of dietary habits. Life Sci. 63: 995-1003.
64. Rajagopalan, S., X. P. Meng, S. Ramasamy, D. G. Harrison, and Z. S. Galis. 1996. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J. Clin. Invest. 98: 2572-2579.
65. Xu, X. P., S. R. Meisel, J. M. Ong, S. Kaul, B. Cercek, T. B. Rajavashisth, B. Sharifi, and P. K. Shah. 1999. Oxidized low-density lipoprotein regulales matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation. 99: 993-998.
66. Yokoyama, M., K. Hirata, R. Miyake, H. Akita, Y. Ishikawa, and H. Fukuzaki. 1990. Lysophosphatidylcholine: essential role in the inhibition of endothelium-dependent vasorelaxation by oxidized low density lipoprotein. Biophys. Res. Commun. 168: 301-308.
67. Mangin, E. L., Jr., K. Kugiyama, J. H. Nguy, S. A. Kerns, and P. D. Henry. 1993. Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta. Circ. Res. 72: 161-166.
68. Deckert, V., L. Persegol, L. Viens, G. Lizard, A. Athias, G. Lallemant, P. Gambert, and L. Lagrost. 1997. Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins. Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation. Circulation. 95: 723-731.
69. Grafe, M., W. Auch-Schwelk, H. Hertel, D. Terbeek, G. Steinheidet, M. Loebe, and E. Fleck. 1998. Human cardiac microvascular and macrovascular endothelial cells respond differently to oxidatively modified LDL. Atherosclerosis. 137: 87-95.
70. Parthasarathy, S., U. P. Steinbrecher, J. Barnett, J. L. Wilztum, and D. Steinberg. 1985. Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein. Proc. Natl. Acad. Sci. USA. 82: 3000-3004.
71. Glomset, J. A., C. D. Mitchell, W. C. King, K. A. Applegate, T. Forte, K. R. Norum, and E. Gjone. 1980. In vitro effects of lecithin:cholesterol acyltransferase on apolipoprotein distribution in familial lecithin:cholesterol acyltransferase deficiency. Ann. NY Acad. Sci. 348: 224-243.
72. Parthasarathy, S., M. T. Quinn, D. C. Schwenke, T. E. Carew, and D. Steinberg. 1989. Oxidative modification of beta-very low density lipoprotein. Potential role in monocyte recruitment and foam cell formation. Arteriosclerosis. 9: 398-404.
73. Moulton, K. S., H. Wu, J. Barnett, S. Parthasarathy, and C. K. Glass. 1992. Regulated expression of the human acetylated low density lipoprotein receptor gene and isolation of promoter sequences. Proc. Natl. Acad. Sci. USA 89: 8102-8106.
74. Tontonoz, P., L. Nagy, J. G. Alvarez, V. A. Thomazy, and R. M. Evans. 1998. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93: 241-252.
75. Jialal, I., E. P. Norkus, L. Cristol, and S. M. Grundy. 1991. beta-Carotene inhibits the oxidative modification of low-density lipoprotein. Biochim. Biophys. Acta. 1086: 134-138.
76. Shaish, A., A. Daugherty, F. O'Sullivan, G. Schonfeld, and J. W. Heinecke. 1995. Beta-carotene inhibits atherosclerosis in hypercholesterolemic rabbits. J. Clin. Invest. 96: 2075-2082.
77. Jialal, I., and C. J. Fuller. 1995. Effect of vitamin E, vitamin C and beta-carotene on LDL oxidation and atherosclerosis. Can. J. Cardiol. 11 Suppl G: 97G-103G.
78. Reaven, P. D., A. Khouw, W. F. Beltz, S. Parthasarathy, and J. L. Witztum. 1993. Effect of dietary antioxidant combinations in humans. Protection of LDL by vitamin E but not by beta-carotene. Arterioscler. Thromb. 13: 590-600.
79. Shaish, A., J. George, B. Gilburd, P. Keren, H. Levkovitz, and D. Harats. 1999. Dietary beta-carotene and alpha-tocopherol combination does not inhibit atherogenesis in an apoE-deficient mouse model. Arterioscler. Thromb. Vasc. Biol. 19: 1470-1475.
80. Staprans, I., J. H. Rapp, X. M. Pan, D. A. Hardman, and K. R. Feingold. 1996. Oxidized lipids in the diet accelerate the development of fatty streaks in cholesterol-fed rabbits. Arterioscler. Thromb. Vasc. Biol. 16: 533-538.
81. Peng, S. K., C. B. Taylor, E. H. Mosbach, W. Y. Huang, J. Hill, and B. Mikkelson. 1982. Distribution of 25-hydroxycholesterol in plasma lipoproteins and its role in atherogenesis. Astudy in squirrel monkeys. Atherosclerosis. 41: 395-402.
82. Meydani, M., R. D. Lipman, S. N. Han, D. Wu, A. Beharka, K. R. Martin, R. Bronson, G. Cao, D. Smith, and S. N. Meydani. 1998. The effect of long-term dietary supplementation with antioxidants. Ann. NY Arad. Sci. 854: 352-360.
83. Gaziano, J. M., A. Hatta, M. Flynn, E.J. Johnson, N. I. Krinsky, P. M. Ridker, C. H. Hennekens, and B. Frei. 1995. Supplementation with beta-carotene in vivo and in vitro does not inhibit low density lipoprotein oxidation. Atherosclerosis. 112: 187-195.
84. Gey, K. F., U. K. Moser, P. Jordan, H. B. Stahelin, M. Eichholzer, and E. Ludin. 1993. Increased risk of cardiovascular disease at suboptimal plasma concentrations of essential antioxidants: an epidemiological update with special attention to carotene and vitamin C. Am. J. Clin. Nutr. 57: 787S-797S.
85. Gey, K. F. 1995. Cardiovascular disease and vitamins. Concurrent correction of 'suboptimal' plasma antioxidant levels may, as important part of 'optimal' nutrition, help to prevent early stages of cardiovascular disease and cancer, respectively. Bibl. Nutr. Dieta. 52: 75-91.
86. Leighton, F., C. Castro, C. Barriga, and E. I. Urquiaga. 1997. Wine and health. Epidemiological studies and possible mechanisms of the protective effects. Rev. Med. Chile. 125: 483-491.
87. Reaven, P., S. Parthasarathy, B. J. Grasse, E. Miller, D. Steinberg, and J. L. Witztum. 1993. Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolemic subjects. J. Clin. Invest. 91: 668-676.
88. Parthasarathy, S., J. C. Khoo, E. Miller, J. Barnett, J. L. Witztum, and D. Steinberg. 1990. Low density lipoprotein rich in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosis. Prac. Natl. Acad. Sci. USA. 87: 3894-3898.
89. Reaven, P., S. Parthasarathy, B. J. Grasse, E. Miller, F. Almazan, F. H. Mattson, J. C. Khoo, D. Steinberg, and J. L. Witztum. 1991. Feasibility of using an oleate-rich diet to reduce the susceptibility of low-density lipoprotein to oxidative modification in humans. Am. J. Clin. Nutr. 54: 701-706.
90. Vinson, J. A., and Y. A. Dabbagh. 1998. Effect of green and black tea supplementation on lipids, lipid oxidation and Fibrinogen in the hamster: mechanisms for the epidemiological benefits of tea drinking. FEBS Lett. 433: 44-46.
91. Fuhrman, B., S. Buch, J. Vaya, P. A. Belinky, R. Coleman, T. Hayek, and M. Aviram. 1997. Licorice extract and its major polyphenol glabridin protect low-density lipoprotein against lipid peroxidation: in vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am. J. Clin. Nutr. 66: 267-275.
92. Visioli, F., G. Bellomo, G. Montedoro, and C. Galli. 1995. Low density lipoprotein oxidation is inhibited in vitro by olive oil constituents. Atherosclerosis. 117: 25-32.
93. Nicolaiew, N., N. Lemort, L. Adorni, B. Berra, G. Montorfano, S. Rapelli, N. Cortesi, and B. Jacotot. 1998. Comparison between extra virgin olive oil and oleic acid rich sunflower oil: effects on postprandial lipemia and LDL susceptibility Io oxidation. Ann. Nutr. Metab. 42: 251-260.
94. Bonanome, A., A. Pagnan, S. Biffanti, A. Opportuno, F. Sorgato, M. Dorella, M. Maiorino, and F. Ursini. 1992. Effect of dietary monounsaturated and polyunsaturated fatty acids on the susceptibility of plasma low density lipoproteins to oxidative modification. Arterioscler. Thromb. 12: 529-533.
95. Hayek, T., B. Fuhrman, J. Vaya, M. Rosenblat, P. Belinky, R. Coleman, A. Elis, and M. Aviram. 1997. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler. Thromb. Vasc. Biol. 17: 2744-2752.
96. Steinbrecher, U. P. 1997. Dietary antioxidants and cardioprotection - fact or fallacy? Can. J. Physiol. Pharmacol. 75: 228-233.
97. Hughes, K. 1995. Diet and coronary heart disease - a review. Ann. Acad. Med. Singapore. 24: 224-229.
98. Fruebis, J., D. A. Bird, J. Pattison, and W. Palinski. 1997. Extent of antioxidant protection of plasma LDL is not a predictor of the antiatherogenic effect of antioxidants. J. Lipid Res. 38: 2455-2464.
99. Steinberg, D., S. Parthasarathy, and T. E. Carew. 1988. In vivo inhibition of foam cell development by probucol in Watanabe rabbits. Am. J. Cardiol. 62: 6B-12B.
100. Daugherty, A., B. S. Zweifel, and G. Schonfeld. 1991. The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits. Br. J. Pharmacol. 103: 1013-1018.
101. Bjorkhem, I., A. Henriksson-Freyschuss, O. Breuer, U. Diczfalusy, L. Berglund, and P. Henriksson. 1991. The antioxidant butylated hydroxytoluene protects againstatherosclerosis. Arterioscler. Thromb. 11: 15-22.
102. Sendobry, S. M., J. A. Cornicelli, K. Welch, T. Bocan, B. Tait, B. K. Trivedi, N. Colbry, R. D. Dyer, S. J. Feinmark, and A. Daugherty. 1997. Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br. J. Pharmacol. 120: 1199-1206.
103. Donaldson, W. E. 1982. Atherosclerosis in cholesterol-fed Japanese quail: evidence for amelioration by dietary vitamin E. Poult. Sci. 61: 2097-2102.
104. Verlangieri, A. J., and M. J. Bush. 1992. Effects of d-alpha-tocopherol supplementation on experimentally induced primate atherosclerosis. J. Am. Coll. Nutr. 11: 131-138.
105. Sparrow, C. P., T. W. Doebber, J. Olszewski, M. S. Wu, J. Ventre, K. A. Stevens, and Y. S. Chao. 1992. Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N′-diphenyl-phenylenediamine. J. Clin. Invest. 89: 1885-1891.
106. Tangirala, R. K., F. Casanada, E. Miller, J. L. Witztum, D. Steinberg, and W. Palinski. 1995. Effect of the antioxidant N,N′-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in apoEdeficient mice. Arterioscler. Thromb. Vasc. Biol. 15: 1625-1630.
107. Stephens, N. G., A. Parsons, P. M. Schofield, F. Kelly, K. Cheeseman, and M. J. Mitchinson. 1996. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) [seecomments]. Lancet. 347: 781-786.
108. Hodis, H. N., W. J. Mack, L. LaBree, L. Cashin-Hemphill, A. Sevanian, R. Johnson, and S. P. Azen. 1995. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. J. Am. Med. Assoc. 273: 1849-1854.
109. Azen, S. P., D. Qian, W. J. Mack, A. Sevanian, R. H. Selzer, C. R. Liu, C. H. Liu, and H. N. Hodis. 1996. Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Orculation. 94: 2369-2372.
110. Tribble, D. L., E. L. Gong, C. Leeuwenburgh, J. W. Heinecke, E. L. Carlson, J. G. Verstuyft, and C. J. Epstein. 1997. Fatty streak formation in fat-fed mice expressing human copper-zinc superoxide dismutase [published erratum appears in Arterioscler. Tromb. Vasc. Biol. 1997. 17: 3363]. Arterioscler. Thromb. Vasc. Biol. 17: 1734-1740.
111. Bowry, V. W., K. U. Ingold, and R. Stocker. 1992. Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. Biochem. J. 288: 341-344.
112. Yamamoto, K., and E. Niki. 1988. Interaction of alpha-tocopherol with iron: antioxidant and prooxidant effects of alpha-tocopherol in the oxidation of lipids in aqueous dispersions in the presence of iron. Biochim. Biophys. Acta. 958: 19-23.
113. Thomas, S. R., J. Neuzil, and R. Stocker. 1996. Cosupplementation with coenzyme Q prevents the prooxidant effect of alphatotopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation. Arterioscler. Thromb. Vasc. Biol. 16: 687-696
114. Witting, P. K., D. Mohr, and R. Stocker. 1999. Assessment of prooxidant activity of vitamin E in human low-density lipoprolein and plasma [In Process Citation]. Methods Enzymol. 299: 362-375.
115. Niki, E. 1991. Action of ascorbic acid as a scavenger of active and stable oxygen radicals. Am. J. Clin. Nutr. 54: 1119S-1124S.
116. Santanam, N., R. Sheni-Brewer, R. McClatchey, P. Z. Castellano, A. A. Murphy, S. Voelkel, and S. Parthasarathy. 1998. Estradiol as an antioxidant: incompatible with its physiological concentrations and function. J. Lipid Res. 39: 2111-2118.
117. Klebanoff, S. J. 1977. Estrogen binding by leukocytes during phagocytosis. J. Exp. Med. 145: 983-998.
118. Jansson, G. 1991. Oestrogen-induced enhancement of myeloperoxidase activity in human polymorphonuclear leukocytes - a possible cause of oxidative stress in inflammatory cells. Free Radical Res. Commun. 14: 195-208.
119. Subbiah, M. T., B. Kessel, M. Agrawal, R. Rajan, W. Abplanalp, and Z. Rymaszewski. 1993. Antioxidant potential of specific estrogens on lipid peroxidation. J. Clin. Endocrinol. Metab. 77: 1095-1097.
120. Hishikawa, K., T. Nakaki, T. Marumo, H. Suzuki, R. Kato, and T. Saruta. 1995. Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett. 360: 291-293.
121. Herrington, D. M., J. Fong, C. T. Sempos, D. M. Black, H. G. Schrott, P. Rautaharju, P. S. Bachorik, R. Blumenthal, S. Khan, and N. K. Wenger. 1998. Comparison of the Heart and Estrogen/ Progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III). Am. Heart. J. 136: 115-124.
122. Hulley, S., D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, and E. Vittinghoff. 1998. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progostin Replacement Study (HERS) Research Group [see comments]. J. Am. Med. Assoc. 280: 605-613.
123. Bird, D. A., R. K. Tangirala, J. Fruebis, D. Steinberg, J. L. Witztum, and W. Palinski. 1998. Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice. J. Lipid Res. 39: 1079-1090.
124. Zhang, S. H., R. L. Reddick, E. Avdievich, L. K. Surles, R. G. Jones, J. B. Reynolds, S. H. Quarfordt, and N. Maeda. 1997. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J. Clin. Invest. 99: 2858-2866.
125. Fruecbis, J., D. Steinberg, H. A. Dresel, and T. E. Carew. 1994. A comparison of the antiatherogenic effects of probucol and of a structuralanalogue of probucol in lowdensity lipoprotein receptor-deficient rabbits. J. Clin. Invest. 94: 392-398.
126. Kamasamy, S., S. Parthasarathy, and D. G. Harrison. 1998. Regulation of endothelial nitric oxide synthase gene expression by oxidized linoleic acid. J. Lipid Res. 39: 268-276.
127. Goss, S. P., B. Kalyanaraman, and N. Hogg. 1999. Antioxidant effects of nitric oxide and nitric oxide donor compounds on low-density lipoprotein oxidation. Methods Enzymol. 301: 444-453.
128. Hernandez-Perera, O., D. Perez-Sala, J. Navarro-Antolin, R. Sanchez-Pascuala, G. Hernandez, C. Diaz, and S. Lamas. 1998. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvasiatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J. Clin. Invest. 101: 2711-2719.
129. Minor, R. L., Jr., P. R. Myers, R. Guerra, Jr., J. N. Bates, and D. G. Harrison. 1990. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J. Clin. Invest 86: 2109-2116.
130. Ramasamy, S., G. R. Drummond, J. Ahn, M. Storek, J. Pohl, S. Parthasarathy, and D. G. Harrison. 1999. Modulation of expression of endothelial nitric oxide synthase by nordihydrognaiaretic acid, a phenolic antioxidant in cultured endothelial cells. Mol. Pharmacol.56: 116-123.
131. Yoshioka, T., T. Homma, B. Meyrick, M. Takeda, T. Moore-Jarrett, V. Kon, and I. Ichikawa. 1994. Oxidants induce transcriptional activation of manganese superoxide dismutase in glomerular cells. Kidney Int. 46: 405-413.
132. Kinscheif, R., H. P. Deigner, C. Usinger, J. Pill, M. Wagner, H. Kamencic, D. Hou, M. Chen, W. Schmiedt, M. Schrader, G. Kovacs, K. Kato, and J. Metz. 1997. Induction of mitochondrial manganese superoxide dismutase in macrophages by oxidized LDL: its relevance in atherosclerosis of humans and heritable hyperlipidemic rabbits. FASEB J. 11: 1317-1328.
133. Stocker, R. 1990. Induction of haem oxygenase as a defence against oxidative stress. Free Radical Res. Commun. 9: 101-112.
134. Ishikawa, K., M. Navab, N. Leitinger, A. M. Fogelman, and A. J. Lusis. 1997. Induction of heme oxygenase-1 inhibits the monocyte transmigration induced by mildly oxidized LDL. J. Clin. Invest. 100: 1209-1216.
135. Agarwal, A., J. Balla, G. Balla, A. J. Groatt, G. M. Vercellotti, and K. A. Nath. 1996. Renal tubular epithelial cells mimic endothelial cells upon exposure to oxidized LDL. Am. J. Physiol. 271: F814-823.
136. Bertling, C. J., F. Lin, and A. W. Girotti. 1996. Role of hydrogen peroxide in the cytotoxic effects of UVA/B radiation on mammalian cells. Photochem. Photobiol. 64: 137-142.
137. Darley-Usmar, V. M., A. Severn, V. J. O'Leary, and M. Rogers. 1991. Treatment of macrophages with oxidized low-density lipoprotein increases their intracellular glutathione content. Biochem. J. 278: 429-434.
138. Sato, H., Y. Takenaka, K. Fujiwara, M. Yamaguchi, K. Abe, and S. Bannai. 1995. Increase in cystine transport activity and glutathione level in mouse peritoneal macrophages exposed to oxidized low-density lipoprotein. Biochem. Res. Commun. 215: 154-159.
139. Wetzstein, C. J., R. A. Shern-Brewer, N. Santanam, N. R. Green, J. K. White-Welkley, and S. Parthasarathy. 1998. Does acute exercise affect the susceptibility of low density lipoprotein to oxidation? Free Radical Biol. Med. 24: 679-682.
140. Shern-Brewer, R., N. Santanam, C. Wetzstein, J. White-Welkley, and S. Parthasarathy. 1998. Exercise and cardiovascular disease: a new perspective. Arterioscler. Thromb. Vasc. Biol. 18: 1181-1187.
141. Sevanian, A., J. Hwang, H. Hodis, G. Gazzolato, P. Avogaro, and G. Bittolo-Bon. 1996. Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler. Thromb. Vasc. Biol. 16: 784-793.
142. Hodis, H. N., D. M. Kramsch, P. Avogaro, G. Bittolo-Bon, G. Cazzolato, J. Hwang, H. Peterson, and A. Sevanian. 1994. Biochemical and cytotoxic characteristics of an in vivo circulating oxidized low density lipoprotein (LDL.-). J. Lipid Res. 35: 669-677.
143. Moriwaki, H., N. Kume, T. Sawamura, T. Aoyama, H. Hoshikawa, H. Ochi, E. Nishi, T. Masaki, and T. Kita. 1998. Ligand specificity of LOX-1, a novel endothelial receptor for oxidized low density lipoprotein. Arterioscler. Thromb. Vasc. Biol. 18: 1541-1547.
144. Ramprasad, M. P., W. Fischer, J. L. Witztum, G. R. Sambrano, O. Quehenberger, and D. Steinberg. 1995. The 94- to 97-kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphalidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc. Natl. Acad. Sci. USA. 92: 9580-9584.
145. Palinski, W., M. E. Rosenfeld, S. Yla-Herttuala, G. C. Gurtner, S. S. Socher, S. W. Butler, S. Parthasarathy, T. E. Carew, D. Steinberg, and J. L. Witztum. 1989. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA. 86: 1372-1376.
146. Calara, F., P. Dimayuga, A. Niemann, J. Thyberg, U. Diezfalusy, J. L. Witztum, W. Palinski, P. K. Shah, B. Cercek, J. Nilsson, and J. Regnstrom. 1998. An animal model to study local oxidation of LDL and its biological effects in the arterial wall. Arterioscler. Thromb. Vasc. Biol. 18: 884-893.
147. Lipton, B. A., S. Parthasarathy, V. A. Ord, S. K. Clinton, P. Libby, and M. E. Rosenfeld. 1995. Components of the protein fraction of oxidized low density lipoprotein stimulate interleukin-1 alpha production by rabbit arterial macrophage-derived foam cells. J. Lipid Res. 36: 2232-2242.
148. Ball, R. Y., J. P. Bindman, K. L. Carpenter, and M. J. Mitchinson. 1986. Oxidized low density lipoprotein induces ceroid accumulation by marine peritoneal macrophages in vitro. Atherosclerosis. 60: 173-181.
149. Quinn, M. T., S. Parthasarathy, L. G. Fong, and D. Steinberg. 1987. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyle/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA. 84: 2995-2998.
150. Hazen, S. L., and J. W. Heinecke. 1997. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J. Clin. Invest. 99: 2075-2081.
151. Colles, S. M., K. C. Irwin, and G. M. Chisolm. 1996. Roles of multiple oxidized LDL lipids in cellular injury: dominance of 7 betahydroperoxycholesterol. J. Lipid Res. 37: 2018-2028.
152. Hazen, S. L., F. F. Hsu, K. Duffin, and J. W. Heinecke. 1996. Molecular chlorine generated by the myeloperoxidase-hydrogen peroxide-chloride system of phagocytes converts low density lipoprotein cholesterol into a family of chlorinated sterols. J. Biol. Chem. 271: 23080-23088.
153. Leeuwenburgh, C., M. M. Hardy, S. L. Hazen, P. Wagner, S. Ohishi, U. P. Steinbrecher, and J. W. Heinecke. 1997. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J. Biol. Chem. 272: 1433-1436.
154. Sugiyama, S., K. Kugiyama, M. Ohgushi, K. Fujimoto, and H. Yasue. 1994. Lysophosphatidylcholine in oxidized low-density lipoprotein increases endothelial susceptibility to polymorphonuclear leukocyte-induced endothelial dysfunction in porcine coronary arteries. Role of protein kinase C. Circ. Res. 74: 565-575.